Alsuma Disease Interactions
There are 4 disease interactions with Alsuma (sumatriptan).
5-HT1 agonists (applies to Alsuma) CAD risk factors
Major Potential Hazard, High plausibility. Applicable conditions: Diabetes Mellitus, History (Familial) - Ischemic Heart Disease, Hyperlipidemia, Menopausal Disorder, Obesity, Smoking
The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD). Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease. As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur. Periodic cardiovascular evaluations should be performed during intermittent, long-term use.
5-HT1 agonists (applies to Alsuma) cardiovascular disease
Major Potential Hazard, High plausibility. Applicable conditions: History - Myocardial Infarction, Cerebral Vascular Disorder, History - Cerebrovascular Disease, Heart Disease, Prinzmetal's Angina, Angina Pectoris, Ischemic Heart Disease
The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic coronary artery disease (CAD), coronary artery vasospasm (including Prinzmetal's angina), cerebrovascular syndromes (stroke or TIA), peripheral vascular disease (including ischemic bowel disease), uncontrolled hypertension, and any other significant underlying cardiovascular disease. 5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of CAD. Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities. However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.
Sumatriptan (applies to Alsuma) liver disease
Major Potential Hazard, High plausibility.
Sumatriptan is contraindicated in patients with severe hepatic impairment. In patients with mild hepatic impairment, a lower dosage is recommended for oral tablets containing sumatriptan; data not available for the intranasal formulation.
Sumatriptan (applies to Alsuma) seizure disorders
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures
Seizures have been reported following the administration of sumatriptan. Therapy with sumatriptan should be administered cautiously in patients with epilepsy or with predisposing conditions associated with a lowered seizure threshold.
Switch to professional interaction data
Alsuma drug interactions
There are 102 drug interactions with Alsuma (sumatriptan).
Alsuma alcohol/food interactions
There are 2 alcohol/food interactions with Alsuma (sumatriptan).
More about Alsuma (sumatriptan)
- Alsuma consumer information
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antimigraine agents
- Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Ubrelvy
Ubrelvy (ubrogepant) tablets are used for the acute treatment of migraine. Includes Ubrelvy side ...
Nurtec ODT
Nurtec ODT (rimegepant) is used to treat acute migraines and prevent episodic migraines, by ...
Qulipta
Qulipta is used to help prevent episodic or chronic migraine headaches in adults. Qulipta is an ...
Imitrex
Imitrex (sumatriptan) is used to treat migraine headaches, with or without aura, in adults ...
Emgality
Emgality (galcanezumab-gnlm) is a CGRP antagonist for the preventive treatment of migraine and for ...
Indocin
Indocin is used for ankylosing spondylitis, back pain, bartter syndrome, bursitis, cluster ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Rayos
Rayos (prednisone, delayed-release) is used to treat rheumatoid arthritis, polymyalgia rheumatica ...
Galcanezumab
Galcanezumab-gnlm (Emgality) is a CGRP antagonist for the preventive treatment of migraine and ...
Dihydroergotamine
Dihydroergotamine Injection information from Drugs.com, includes Dihydroergotamine Injection side ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.